Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dociparstat sodium - Cantex Pharmaceuticals

Drug Profile

Dociparstat sodium - Cantex Pharmaceuticals

Alternative Names: CX-01; DSTAT; ODSH; PGX-100; PGX-ODSH-2013-AML-1

Latest Information Update: 19 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ParinGenix
  • Developer Cantex Pharmaceuticals; Chimerix
  • Class Anti-inflammatories; Anticoagulants; Antineoplastics; Heparins; Ischaemic heart disorder therapies; Polysaccharides
  • Mechanism of Action Cathepsin G inhibitors; Chemokine CXCL12 inhibitors; CXCR4 receptor antagonists; HMGB1 protein inhibitors; Leucocyte elastase inhibitors; P selectin inhibitors; Platelet factor 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Acute lung injury; Acute myeloid leukaemia; Blood coagulation disorders; Brain injuries; Chronic obstructive pulmonary disease; Lung cancer; Myelodysplastic syndromes; Myocardial infarction; Pancreatic cancer; Reperfusion injury; Solid tumours; Thrombocytopenia

Most Recent Events

  • 12 Jul 2022 Chimerix terminates the license and development agreement with Cantex for dociparstat sodium
  • 16 May 2022 Chimerix terminates phase III DASH-AML trial in Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA (IV, Infusion) due to slow recruitment (NCT04571645)
  • 31 Dec 2021 Chimerix has several US and foreign issued patents and pending US and foreign applications for Dociparstat sodium in USA prior to December 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top